Pd-L1 Tumor Expression
VIDEO: Immunotherapy alone shows benefit in older patients with NSCLC
Ravi Salgia, MD, PhD, spoke with Healio about findings presented at ASCO Annual Meeting from a FDA pooled analysis of first-line treatment options for patients with PD-L1 advanced non-small cell lung cancer.
Sugemalimab extends PFS in stage III NSCLC
Cemiplimab prolongs OS in NSCLC with high PD-L1 expression
Cemiplimab-rwlc monotherapy extended OS compared with first-line platinum doublet chemotherapy for certain patients with advanced non-small cell lung cancer, according to study findings presented at ESMO Virtual Congress 2020.
Should overexpression of PD-L1 guide patient selection for lung cancer treatment?
The programmed death-1 receptor and its programmed death ligand-1 are key components of an immune checkpoint that has now been successfully targeted in several malignancies. Antibodies directed against PD-1 (pembrolizumab and nivolumab) as well as PD-L1 (atezolizumab and durvalumab) are now approved in a number of malignancies, including non-small cell lung cancer. Of these, only pembrolizumab treatment is contingent upon verification of PD-L1 expression.
FDA expands Tecentriq approval for metastatic lung cancer
The FDA expanded the approval of atezolizumab to include first-line monotherapy of patients with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression.